With a market capitalization (market cap) of $2.01B — a measure of how much the company is worth — Novocure Ltd is the 2111th most valuable company in Healthcare as of August 18, 2026. Shares trade at $17.24, down +1.65% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Visit websiteAs of August 18, 2026, Novocure Ltd (NVCR) is worth $2.01B — this is its market capitalization, the total value of all its outstanding shares.
Novocure Ltd’s market cap is $2.01B, which ranks it #2111 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Novocure Ltd (NVCR) shares trade at $17.24, down 1.65% on the day, as of August 18, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025